Tango Therapeutics, Inc. - stock earnings
TNGX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -30.8 million USD | 5.4 million USD |
| 2023Q3 | -22.3 million USD | 10.7 million USD |
| 2023Q2 | -20.7 million USD | 14.6 million USD |
| 2023Q1 | -25.7 million USD | 5.8 million USD |
| 2022Q4 | -29.1 million USD | 6.4 million USD |
| 2022Q3 | -28.2 million USD | 6.9 million USD |
| 2022Q2 | -24.9 million USD | 5.8 million USD |
| 2022Q1 | -25.0 million USD | 5.8 million USD |
| 2021Q4 | -22.0 million USD | 5.7 million USD |
| 2021Q3 | -19.6 million USD | 6.8 million USD |
| 2021Q2 | -4.5 million USD | 18.2 million USD |
| 2021Q1 | -12.1 million USD | 6.4 million USD |
| 2020Q4 | -8.9 million USD | 9.1 million USD |
| 2020Q3 | -26.8 million USD | -11.3 million USD |
TNGX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -101.7 million USD | 36.5 million USD |
| 2022 | -108.2 million USD | 24.9 million USD |
| 2021 | -58.2 million USD | 37.0 million USD |
| 2020 | -51.9 million USD | 7.7 million USD |
| 2019 | -14.1 million USD | 24.6 million USD |
TNGX
Price: $7.44
52 week price:
Earnings Per Share: -1.08 USD
P/E Ratio: -11.60
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 179400
Market Capitalization: 784.4 million